TUSTIN, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals,
Inc. (Nasdaq: PPHM), today announced that noted cancer researcher Bruce
Chabner, M.D., will serve as a clinical advisor to the company on the design
of clinical trials for the bavituximab cancer program. Dr. Chabner is
currently the clinical director of Massachusetts General Hospital (MGH) Cancer
Center, chief of hematology and oncology at MGH and a professor of medicine at
Harvard Medical School. Before coming to MGH, Dr. Chabner had a distinguished
25-year career at the National Cancer Institute (NCI), including serving as
scientific director and director of the Division of Cancer Treatment. He has
received numerous honors and awards, including the U.S. Public Health
Service's Distinguished Service Award for his leadership in the development
and approval of paclitaxel (Taxol(R)), a mainstay of current cancer therapy.
